Michael J. Fox Foundation Awards $2.1 Million to Drive Six Industry Teams' Pre-Clinical Development of Neuroprotective Parkinson's Therapies
NEW YORK, NY ó As part of its mission to speed development of transformative treatments for Parkinsonís disease, The Michael J. Fox Foundation for Parkinsonís Research announced a total of $2.1 million in awards to six biotech and pharmaceutical companies under its industry-exclusive Therapeutics Development Initiative (TDI). The funding will drive pre-clinical projects pushing forward investigations of promising neuroprotective therapeutic targets for Parkinsonís.
Three teams will focus on strategies to address inflammation and oxidative stress, while two will investigate ways to target the Parkinsonís-implicated protein alpha-synuclein (including FoldRx Pharmaceuticalsí continuing investigation of small-molecule drug candidates to inhibit alpha-synuclein toxicity, funded by MJFF since 2007). The remaining team will investigate HDACs, a family of enzymes that have been shown to enhance expression of potential protective factors in preclinical models of PD and may also regulate clearance of toxic proteins.
While MJFF welcomes applications from industry researchers under all of its programs, TDI ó first launched in 2006 ó is the Foundationís only industry-exclusive funding stream. It is a key element of MJFFís strategy to Ďde-riskí preclinical PD research for biotech and pharmaceutical companies, thus expanding industry investment in Parkinsonís therapeutic development and helping push the most promising research to the next stage.
Projects selected for funding are listed below. Detailed information, including grant abstracts and researcher bios, is available in the Searchable Database of Funded Grants at www.michaeljfox.org/research. As with all MJFF grants, full funding is contingent on the achievement of predetermined, specific milestones and on researchersí agreement to make the results of their work available to the Parkinsonís research community.
Projects Focused on Inflammation and Oxidative Stress
Design of Neuroprotective Drugs to Reduce Oxidative Damage and Alpha-Synuclein Toxicity in Parkinsonís Disease
Stig Hansen, PhD, Carmot Therapeutics, Inc.
Targeting TLR2 as a Novel Therapy for Parkinsonís Disease
Andrew Parker, PhD, Opsona Therapeutics LTD
An Innovative Drug for Disease-Modifying Treatment of Parkinsonís Disease
Philipp Wabnitz, PhD, InterMed Discovery GmbH
Projects Focused on Alpha-Synuclein
Determination and Validation of the Molecular Target of J3, a Neuroprotective Lead Compound, for Its Optimization as a Disease-modifying Candidate for Parkinsonís Disease
Christine Bulawa, PhD, FoldRx Pharmaceuticals, Inc.
Developing Autophagy Enhancers as Disease-modifying Therapeutics for Parkinsonís Disease
John Dunlop, PhD, Pfizer Global Research and Development
Potential Efficacy of a Novel, Orally Bioavailable, CNS-penetrant HDAC Inhibitor in Pre-clinical Models of Parkinsonís Disease
Holger Patzke, PhD, Envivo Pharmaceuticals
TDI is launched bi-annually with applications accepted each spring and fall. It has been enthusiastically received by industry researchers. To date the Foundation has awarded $18.6 million total for 39 industry-led projects under the initiative.